论文部分内容阅读
目的观察华蟾素注射液配合吉西他滨与顺铂治疗非小细胞肺癌(NSCLC)的临床疗效。方法将217例NSCLC患者随机分为治疗组109例和对照组108例,对照组治疗第1、8天予吉西他滨1000mg/m2静脉滴注,顺铂80～100mg/m2分2～3天静脉滴注;治疗组在对照组的基础上静脉滴注华蟾素20ml。28天为1个周期,治疗3个周期后对临床疗效、受益率、生存率、肿瘤进展时间、生活质量以及不良反应进行评估。结果治疗组与对照组的有效率分别为55.96%和37.96%,两组比较差异有统计学意义(P<0.05);治疗组和对照组的中位肿瘤进展分别为30周和24周,差异有统计学意义(P<0.05);与对照组比较,治疗组患者6个月、1年、2年的生存率明显上升(P<0.05)。两组治疗后患者生活质量评分明显提高(P<0.05),但治疗后治疗组和对照组比较差异无统计学意义(P>0.05)。与对照组比较,治疗组不良反应发生率明显下降(P<0.05)。结论华蟾素注射液配合吉西他滨与顺铂疗法有助于NSCLC患者临床症状的改善和临床疗效、生活质量的提高。
Objective To observe the clinical efficacy of cinobufagin injection combined with gemcitabine and cisplatin in the treatment of non-small cell lung cancer (NSCLC). Methods A total of 217 patients with NSCLC were randomly divided into treatment group (n = 109) and control group (n = 108). The control group received gemcitabine 1000 mg / m 2 intravenously on Days 1 and 8 and intravenous infusion of cisplatin 80 ~ 100 mg / Note; treatment group in the control group on the basis of intravenous infusion of cinobufacini 20ml. 28 days for a period of three cycles after treatment of clinical efficacy, benefit rate, survival rate, tumor progression time, quality of life and adverse reactions were evaluated. Results The effective rates of the treatment group and the control group were 55.96% and 37.96%, respectively, with significant difference between the two groups (P <0.05). The median tumor progression rates in the treatment group and the control group were 30 weeks and 24 weeks, respectively (P <0.05). Compared with the control group, the survival rate of patients in the treatment group at 6 months, 1 year and 2 years increased significantly (P <0.05). After treatment, the quality of life scores of patients in the two groups were significantly improved (P <0.05), but there was no significant difference between the treatment group and the control group after treatment (P> 0.05). Compared with the control group, the incidence of adverse reactions in the treatment group decreased significantly (P <0.05). Conclusion Cinobufagin injection combined with gemcitabine and cisplatin can help to improve the clinical symptoms, clinical efficacy and quality of life in NSCLC patients.